Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy

Imagem de Miniatura
Arquivos
art_RAPOSO_Grade_2_disabilities_in_leprosy_patients_from_Brazil_2018.PDF (1.25 MB)
Citações na Scopus
32
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
RAPOSO, Marcos Tulio
REIS, Martha Cerqueira
CAMINHA, Ana Virginia de Queiroz
HEUKELBACH, Jorg
PARKER, Lucy Anne
PASTOR-VALERO, Maria
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.12, n.7, article ID e0006645, 12p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Leprosy continues to be a public health problem in many countries. Difficulties faced by health services include late diagnosis, under-reporting of new cases, adequate monitoring of disabilities and treatment. Furthermore, systematic follow-up after completion of treatment is important, when new disabilities may occur, or existing disabilities may get worse. The objective of the present study was to determine the prevalence of leprosy-associated grade 2 disabilities (G2D) after completion of multidrug therapy (MDT) and to identify factors associated with G2D. Methods We performed a cross-sectional study of 222 leprosy cases registered in Vitoria da Conquista, Bahia state, Brazil from 2001-2014. We performed a clinical examination of the study participants and collected socio-economic and clinical information by interview. We identified factors associated with grade 2 disability (G2D) using logistic regression. Results In total, 38 (17.1%) participants were diagnosed with G2D, and 106 (47.7%) with grade 1 disabilities (G1D). The following independent factors were significantly associated with G2D: occurrence of leprosy reaction (adjusted OR = 2.5; 95% CI = 1.09-5.77), thickening and/or tenderness of one or more nerve trunks (adjusted OR = 3.0; CI = 1.13-8.01) and unemployment (adjusted OR = 7.17; CI = 2.44-21.07). Conclusions This study shows that physical disabilities remain after completion of MDT and frequently occur in an endemic area in Brazil. Finding new ways to reduce the burden of disability are urgently needed, and may include systematic follow-up of patients after treatment completion combined with evidence-based preventative measures.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/28220
Referências
  1. Alencar MJF, 2014, CAD SAUDE COLET, V21, P450
  2. [Anonymous], 2017, Wkly Epidemiol Rec, V92, P501
  3. Antunes DE, 2013, MEM I OSWALDO CRUZ, V108, P901, DOI 10.1590/0074-0276130222
  4. Carvalho M. A. J., 2013, Hansenologia Internationalis, V38, P47
  5. Clayton DHM, 1993, STATISTICAL METHODS
  6. Croft RP, 2000, LEPROSY REV, V71, P154
  7. Croft RP, 2003, LEPROSY REV, V74, P35
  8. de Castro LE, 2014, LEPROSY REV, V85, P208
  9. de Souza EA, 2018, REV SAUDE PUBL, V52, DOI [10.11606/s1518-8787.2018052000335, 10.11606/S1518-8787.2018052000335]
  10. Draper NR, 1981, APPL REGRESSION ANAL, pxiv
  11. Ebenso J, 2007, DISABIL REHABIL, V29, P689, DOI 10.1080/09638280600926587
  12. Penna MLF, 2013, LEPROSY REV, V84, P308
  13. Freitas LRS, 2014, TROP MED INT HEALTH, V19, P1216, DOI 10.1111/tmi.12362
  14. Ramos JMH, 2010, REV SOC BRAS MED TRO, V43, P293, DOI 10.1590/S0037-86822010000300016
  15. Instituto Brasileiro de Geografia e Estatistica, INF MUN BRAS
  16. Kumar A, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000361
  17. Kumar B, 2004, INT J LEPROSY, V72, P125, DOI 10.1489/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2
  18. Lockwood DN, 2012, INT HEALTH, V4, P77, DOI 10.1016/j.inhe.2011.09.006
  19. Ministerio da Saude. Gabinete do Ministro, APR DIR VIG AT CONTR
  20. Ministerio da Saude. Situacde Saude, 2017, IND MORB
  21. Monteiro LD, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006655, 10.1590/s1518-8787.2017051006655]
  22. Monteiro Lorena Dias, 2014, Rev. bras. epidemiol., V17, P91, DOI 10.1590/1415-790X201400010008ENG
  23. Monteiro LD, 2013, CAD SAUDE PUBLICA, V29, P909, DOI 10.1590/S0102-311X2013000500009
  24. Moschioni C, 2010, REV SOC BRAS MED TRO, V43, P19, DOI 10.1590/S0037-86822010000100005
  25. Motta ACF, 2012, CLINICS, V67, P1145, DOI 10.6061/clinics/2012(10)05
  26. Montenegro RMN, 2012, CAD SAUDE PUBLICA, V28, P31, DOI 10.1590/S0102-311X2012000100004
  27. Neves TVN, 2015, REV APS, P335
  28. Pimentel Maria Inês Fernandes, 2004, An. Bras. Dermatol., V79, P169, DOI 10.1590/S0365-05962004000200005
  29. Portal da Saude, DIR VIG AT HANS COM
  30. Richardus JH, 2007, LEPROSY REV, V78, P330
  31. Richardus JH, 2004, INT J EPIDEMIOL, V33, P337, DOI 10.1093/ije/dyg225
  32. Rodrigues A, 2000, HANSEN INT, V25, P7
  33. Rodrigues NC, 2017, LEPROSY REV, V88, P85
  34. Sales AM, 2013, TROP MED INT HEALTH, V18, P1145, DOI 10.1111/tmi.12156
  35. Schuring RP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000283
  36. Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
  37. Sinha A, 2010, Indian J Lepr, V82, P137
  38. Suchonwanit P, 2015, DERMAT RES PRACT, DOI 10.1155/2015/253154
  39. Nardi SMT, 2012, REV SAUDE PUBL, V46, P969, DOI 10.1590/s0034-89102013005000002
  40. Nardi SMT, 2011, LEPROSY REV, V82, P55
  41. van Brakel WH, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.18394
  42. Walker SL, 2008, LEPROSY REV, V79, P372
  43. Wilder-Smith EP, 2008, NAT CLIN PRACT NEURO, V4, P656, DOI 10.1038/ncpneuro0941
  44. Withington SG, 2003, LEPROSY REV, V74, P120
  45. World Health Organization, 2015, WHO GLOB DIS ACT PLA
  46. World Health Organization, 2017, GLOB LEPR STRAT 2016
  47. World Health Organization (WHO), 2016, WKLY EPIDEMIOL REC, V91
  48. World Health Organization (WHO), 2016, GLOB LEPR STRAT 2016
  49. 2012, WHO TECH REP SER, V968, P1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03